The European Patent Office grants patent for tasquinimod for treatment of multiple myeloma
January 09 2017 - 7:08AM
Lund January 9, 2017 - Active Biotech AB (Nasdag Stockholm:
ACTI) announces today that the European Patent Office has
decided to grant Active Biotech's patent application covering
tasquinimod for use in the treatment of multiple myeloma. The
patent will be granted as European Patent No. 3041472 on February
1, 2017 and has a duration lasting until 2035.
For further information, please
contact:
Tomas
Leanderson, President & CEO Tel: +46 46 19 20 95
Hans Kolam, CFO Tel: +46 46 19 20 44
|
Active Biotech AB(Org.nr
556223-9227)Box 724, 220 07 LundTel: +46 46 19 20 00 |
About tasquinimod Tasquinimod is an immunomodulatory,
anti-metastatic and anti-angiogenic compound that affects the
tumor's ability to grow and spread. The development of tasquinimod
has previously been focused on the treatment of prostate cancer
with clinical proof of concept and a good safety profile shown in
Phase 2 and 3 studies. Tasquinimod's mechanism of action is
broadly applicable as anti-tumor treatment and very good results
have been achieved in models for multiple myeloma, a blood cancer
with a high medical need. Active Biotech is seeking a partner for
the continued development of tasquinimod in multiple myeloma.
Active Biotech AB (publ) (Nasdag Stockholm: ACTI) is a
biotechnology company with focus on neurodegenerative/inflammatory
diseases and cancer. Laquinimod, an orally administered small
molecule with unique immunomodulatory properties, is in pivotal
Phase 3 development for the treatment of relapsing remitting
multiple sclerosis. Also, laquinimod is in Phase 2 development for
the treatment of primary progressive multiple sclerosis and
Huntington's disease. Furthermore, commercial activities are
conducted for the tasquinimod, paquinimod and SILC projects. Please
visit www.activebiotech.com for more information.
This information is information that Active Biotech AB is
obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency
of the contact person set out above, at 13.00 pm CET on January 9,
2017.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/54311b72-eb9f-4451-ac41-4c9d3b892f19
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024